Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855882 | 1.00 | HPGD (0.61) | HPGDALDH1A1GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL29565081 | 1.00 | HPGD (0.61) | HPGDALDH1A1GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL13373550 | 0.99 | HPGD (0.58) | HPGDALDH1A1GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL5805385 | 0.89 | ALDH1A1 (0.70) | HPGDALDH1A1GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL14559795 | 0.87 | SMN1; SMN2 (0.52) | HPGDALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL12431600 | 0.87 | ALDH1A1 (0.71) | HPGDALDH1A1GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL22999769 | 0.86 | KDM4E (0.55) | HPGDALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL111568 | 0.86 | ALDH1A1 (0.54) | HPGDALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL13646643 | 0.86 | SMN1; SMN2 (0.60) | HPGDALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL3153203 | 0.86 | SMN1; SMN2 (0.57) | HPGDALDH1A1SMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | HPGD 2284/4885ALDH1A1 315/4885GRIA3 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.